TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23079373

Group type: EXPERIMENTAL
Intervention: 50 mg mirabegron
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 100 mg mirabegron
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 20627289

Group type: EXPERIMENTAL
Intervention: Blue-light cystoscopy and transurethral resection of bladder tumors (TURBT)
Number of subjects: 446

Group type: COMPARATOR
Intervention: Standard cystoscopy and resection
Number of subjects: 446
Study: 18226993

Group type: EXPERIMENTAL
Intervention: Alendronate (bisphosphonate group)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 12
Study: 17136293

Group type: EXPERIMENTAL
Intervention: Second-generation antihistamines
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Third-generation antihistamines
Number of subjects: 0
Study: 15078430

Group type: EXPERIMENTAL
Intervention: Clotrimazole 500 mg single dose vaginal tablet (VT)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Clotrimazole 10% single dose vaginal cream (VC)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Fluconazole 150 mg single dose oral capsule (Diflucan)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Clotrimazole 500 mg VT and Clotrimazole 10% VC
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: All treatments (Clotrimazole and Fluconazole)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Patients with mycological recurrence
Number of subjects: 88
Study: 11269778

Group type: COMPARATOR
Intervention: Thrombolysis (with recombinant tissue plasminogen activator)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Primary PTCA with stent implantation
Number of subjects: 44

Group type: COMPARATOR
Intervention: Thrombolysis
Number of subjects: 44
Study: 9668994

Group type: EXPERIMENTAL
Intervention: Early extraction of third molars
Number of subjects: 164

Group type: COMPARATOR
Intervention: Retention of third molars
Number of subjects: 164
Study: 8001522

Group type: EXPERIMENTAL
Intervention: Riboflavin intake (average daily intake above 0.5 mg/1000 kcal)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: EGRAC measurement (functional test for riboflavin status)
Number of subjects: 60
Study: 3275601

Group type: EXPERIMENTAL
Intervention: Total lymphoid irradiation (TLI)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Sham irradiation
Number of subjects: 40
Study: 29903900

Group type: EXPERIMENTAL
Intervention: Higher baseline log-transformed suPAR
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Higher baseline log-transformed suPAR in patients with two APOL1 risk alleles
Number of subjects: 0
Study: 28414008

Group type: EXPERIMENTAL
Intervention: Community-based participatory nutrition promotion (CPNP) programme
Number of subjects: 876
Study: 25236783

Group type: EXPERIMENTAL
Intervention: Higher hemoglobin measurements at baseline
Number of subjects: 949
Study: 24047591

Group type: EXPERIMENTAL
Intervention: Whitacre needle
Number of subjects: 1376

Group type: COMPARATOR
Intervention: Quincke needle
Number of subjects: 1376
Study: 20972346

Group type: EXPERIMENTAL
Intervention: Thrust joint manipulation (TJM) to the lumbar spine
Number of subjects: 35

Group type: COMPARATOR
Intervention: Sham manipulation treatment
Number of subjects: 35
Study: 18438113

Group type: EXPERIMENTAL
Intervention: Sodium hyaluronate‐based bioresorbable membrane (Seprafilm)
Number of subjects: 150
Study: 17136692

Group type: EXPERIMENTAL
Intervention: CABG plus an experimental aortic catheter
Number of subjects: 1117

Group type: COMPARATOR
Intervention: Standard CABG
Number of subjects: 1117
Study: 12904634

Group type: EXPERIMENTAL
Intervention: Critical velocity (vcrit)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Anaerobic distance capacity (ADC)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Distance limit (dlim) and time limit (tlim) relationship
Number of subjects: 34
Study: 10691822

Group type: EXPERIMENTAL
Intervention: Endoscopic laser ablation of the prostate (ELAP)
Number of subjects: 151

Group type: COMPARATOR
Intervention: Transurethral resection of the prostate (TURP)
Number of subjects: 151
Study: 9084065

Group type: EXPERIMENTAL
Intervention: 30 mg oral adinazolam mesylate SR tablets
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: 10 mg parenteral (i.v.) adinazolam mesylate
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: 30 mg i.v. NDMAD
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study: 8441129

Group type: EXPERIMENTAL
Intervention: Clobetasol propionate (.05%)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Testosterone (2%)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Progesterone (2%)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Cream based preparation
Number of subjects: 79
Study: 3538742

Group type: EXPERIMENTAL
Intervention: Pulsatile insulin infusion (1 1/2 to 2 1/4 min pulses followed by 10 1/2 to 9 3/4 min intervals)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Continuous insulin infusion (0.45 mU/kg X min)
Number of subjects: 8
Study: 30577730

Group type: COMPARATOR
Intervention: Self-affirmation
Number of subjects: 128

Group type: COMPARATOR
Intervention: Moderately-severe health warnings
Number of subjects: 128

Group type: COMPARATOR
Intervention: Highly-severe health warnings
Number of subjects: 128
Study: 27171969

Group type: EXPERIMENTAL
Intervention: Topical Furosemide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Systemic corticosteroids
Number of subjects: 0
Study: 24882604

Group type: EXPERIMENTAL
Intervention: Instructional video in Spanish
Number of subjects: 20
Study: 21556816

Group type: EXPERIMENTAL
Intervention: Aerobic training 3×/week for 16 weeks
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Resistance training 3×/week for 16 weeks
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Higher adherence to training (≥75% attendance, n = 8)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Lower adherence to training (<75% attendance, n = 10)
Number of subjects: 26
Study: 21098442

Group type: EXPERIMENTAL
Intervention: Intracoronary abciximab (0.25 mg/kg)
Number of subjects: 534

Group type: COMPARATOR
Intervention: Intravenous abciximab (0.25 mg/kg)
Number of subjects: 534
Study: 18950458

Group type: EXPERIMENTAL
Intervention: DaunoXome (DNX) 80 mg/m(2) days 1‐3 plus cytarabine (AraC; 100 mg/m(2) days 1‐7)
Number of subjects: 301

Group type: COMPARATOR
Intervention: Daunorubicin (DNR) 45 mg/m(2) days 1‐3 plus cytarabine (AraC; 100 mg/m(2) days 1‐7)
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: DaunoXome (DNX) after complete remission
Number of subjects: 301

Group type: COMPARATOR
Intervention: Daunorubicin (DNR) after complete remission
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: DaunoXome (DNX) in long-term follow-up
Number of subjects: 301
Study: 15899106

Group type: EXPERIMENTAL
Intervention: Ezetimibe 10mg co-administered with simvastatin 10mg or 20mg
Number of subjects: 418

Group type: COMPARATOR
Intervention: Placebo co-administered with simvastatin 10mg or 20mg
Number of subjects: 418
Study: 12730519

Group type: EXPERIMENTAL
Intervention: Graded aerobic exercise programme
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Relaxation therapy
Number of subjects: 93

Group type: COMPARATOR
Intervention: No intervention (Control)
Number of subjects: 93
Study: 11780237

Group type: EXPERIMENTAL
Intervention: Scaling and root planing combined with local application of 2% minocycline hydrochloride ointment (Periocline)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Scaling and root planing alone (Control)
Number of subjects: 31
Study: 8829939

Group type: EXPERIMENTAL
Intervention: diclofenac 75 mg intramuscularly (i.m.)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: ketorolac 30 mg intramuscularly (i.m.)
Number of subjects: 200

Group type: COMPARATOR
Intervention: diclofenac 50 mg orally
Number of subjects: 200

Group type: COMPARATOR
Intervention: 2 mL NaCl i.m.
Number of subjects: 200
Study: 1867962

Group type: EXPERIMENTAL
Intervention: Intravenous cisapride 10 mg
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 6833967

Group type: EXPERIMENTAL
Intervention: Sigmoidoscopy training
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Barium enemas accompanied by sigmoidoscopy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: All participating physicians
Number of subjects: 0
Study: 31995688

Group type: EXPERIMENTAL
Intervention: Eradication therapy (lansoprazole [30 mg], amoxicillin [1000 mg], and clarithromycin [500 mg], each taken twice daily for 7 days)
Number of subjects: 1676

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1676

Group type: EXPERIMENTAL
Intervention: H. pylori eradication
Number of subjects: 1676

Group type: EXPERIMENTAL
Intervention: Persistent H. pylori infection
Number of subjects: 1676

Group type: EXPERIMENTAL
Intervention: Adverse events in treatment group
Number of subjects: 1676
Study: 30726234

Group type: EXPERIMENTAL
Intervention: Anodal tDCS (2.0 mA for 20 minutes)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Cathodal tDCS (2.0 mA for 20 minutes)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Sham tDCS (2.0 mA for 20 minutes)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: All tDCS conditions (anodal, cathodal, sham)
Number of subjects: 36
Study: 30243993

Group type: EXPERIMENTAL
Intervention: Elevated Syndecan-1 levels (≥ 40 ng/mL)
Number of subjects: 512

Group type: COMPARATOR
Intervention: Patients who did not develop sepsis
Number of subjects: 512

Group type: EXPERIMENTAL
Intervention: Patients who developed sepsis
Number of subjects: 512

Group type: EXPERIMENTAL
Intervention: Elevated Syndecan-1 status, Injury Severity Score (ISS), and total blood transfused
Number of subjects: 512
Study: 27187770

Group type: EXPERIMENTAL
Intervention: Good Psychiatric Management (GPM) intervention over 10 sessions
Number of subjects: 40
Study: 25054648

Group type: COMPARATOR
Intervention: Inextensible lumbosacral orthosis (iLSO)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Extensible lumbosacral orthosis (eLSO)
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Standard care (SC)
Number of subjects: 98
Study: 22414352

Group type: EXPERIMENTAL
Intervention: Transpapillary injection
Number of subjects: 200

Group type: COMPARATOR
Intervention: Conventional palatal injection
Number of subjects: 200
Study: 20814766

Group type: EXPERIMENTAL
Intervention: Alpha-linolenic acid (ALA) intake (1.2-3.6 g/d)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Alpha-linolenic acid (ALA) intake
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Observational evidence for ALA
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Alpha-linolenic acid (ALA) status
Number of subjects: 0
Study: 17692522

Group type: EXPERIMENTAL
Intervention: Bright light therapy (5000lx, 100 cm distance)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Control group (natural lighting environment)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Bright light therapy
Number of subjects: 11

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 11
Study: 15866495

Group type: EXPERIMENTAL
Intervention: 20 mg AJA
Number of subjects: 21
Study: 12469271

Group type: EXPERIMENTAL
Intervention: NT-pro-BNP
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: BNP
Number of subjects: 150
Study: 10708321

Group type: EXPERIMENTAL
Intervention: Nurse-delivered relapse prevention intervention
Number of subjects: 238

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 238
Study: 9187185

Group type: EXPERIMENTAL
Intervention: Amlodipine 2.5 mg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Felodipine ER 2.5 mg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Amlodipine 5 mg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Felodipine ER 5 mg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Amlodipine 10 mg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Felodipine ER 10 mg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Felodipine ER
Number of subjects: 10
Study: 1414299

Group type: EXPERIMENTAL
Intervention: Indomethacin 1% ophthalmic solution
Number of subjects: 56

Group type: COMPARATOR
Intervention: Standard preoperative dilation regime
Number of subjects: 56
Study: 2865930

Group type: EXPERIMENTAL
Intervention: PMP + D-penicillamine (DPA) - 500 mg/day
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: PMP + sulphasalazine (SAS) - 2.0 g/day
Number of subjects: 45

Group type: COMPARATOR
Intervention: PMP only
Number of subjects: 45
Study: 30667283

Group type: EXPERIMENTAL
Intervention: NT-proBNP
Number of subjects: 1736

Group type: EXPERIMENTAL
Intervention: Cystatin C
Number of subjects: 1736

Group type: EXPERIMENTAL
Intervention: IL-6
Number of subjects: 1736
Study: 28631896

Group type: EXPERIMENTAL
Intervention: 0.75% Boric acid gel
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 48
Study: 27379654

Group type: EXPERIMENTAL
Intervention: Iloperidone
Number of subjects: 303

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 303
Study: 24801644

Group type: EXPERIMENTAL
Intervention: Infusion set placed on the buttock
Number of subjects: 6

Group type: COMPARATOR
Intervention: Infusion set placed on the abdomen
Number of subjects: 6
Study: 22109950

Group type: EXPERIMENTAL
Intervention: Remote video auditing with feedback
Number of subjects: 60542

Group type: COMPARATOR
Intervention: Remote video auditing without feedback
Number of subjects: 60542
Study: 20237221

Group type: EXPERIMENTAL
Intervention: Various proposed solutions to improve value in cancer care; specific interventions not detailed.
Number of subjects: 0
Study: 19025668

Group type: EXPERIMENTAL
Intervention: Multifaceted podiatry intervention (customized insoles, footwear advice, home-based exercise program, falls prevention education booklet)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Usual care (routine podiatry: nail care and callus debridement)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Multifaceted podiatry intervention
Number of subjects: 300

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 300
Study: 16162440

Group type: EXPERIMENTAL
Intervention: Ciprofibrate treatment
Number of subjects: 29

Group type: COMPARATOR
Intervention: Diet-only
Number of subjects: 29
Study: 12941195

Group type: EXPERIMENTAL
Intervention: Adjuvant hormone therapy using goserelin (LHRH agonist)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adjuvant hormone therapy using bilateral orchiectomy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adjuvant hormone therapy using bicalutamide 150 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combined androgen blockade (medical or surgical castration with antiandrogen)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: LHRH agonists (e.g., goserelin)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nonsteroidal antiandrogens
Number of subjects: 0
Study: 10380836

Group type: EXPERIMENTAL
Intervention: Intermittent cyclical etidronate (400 mg daily for 2 weeks) and calcium (500 mg daily for 11 weeks)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Intermittent cyclical placebo with calcium
Number of subjects: 28
Study: 8671814

Group type: COMPARATOR
Intervention: Diabetic patients at baseline
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Diabetic subjects at follow-up
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Normoalbuminuric patients (UAER < 30mg/24 h)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Microalbuminuric subjects
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Baseline serum insulin concentration
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Baseline serum insulin concentration and diuretic therapy
Number of subjects: 0
Study: 2065824

Group type: EXPERIMENTAL
Intervention: Intensive neurodevelopmental therapy (NDT)
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Upper-extremity inhibitive casting
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Casting with NDT
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Intensive therapy alone
Number of subjects: 73

Group type: COMPARATOR
Intervention: Regular therapy
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: NDT plus casting
Number of subjects: 73
Study: 30118533

Group type: EXPERIMENTAL
Intervention: Computer-Assisted Implant Planning and Placement (CAIPP) - Test 1 (T1, n = 24)
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Computer-Assisted Implant Planning and Placement (CAIPP) - Test 2 (T2, n = 23)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Conventional protocol (C, n = 26)
Number of subjects: 73
Study: 26806668

Group type: EXPERIMENTAL
Intervention: Minute ventilation-targeted adaptive servo-ventilation (MV-ASV) during sleep in addition to optimized medical therapy (active therapy)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Optimized medical therapy alone (usual care)
Number of subjects: 126
Study: 25153328

Group type: EXPERIMENTAL
Intervention: Daily liquorice consumption (glycyrrhizin dose 290‐370 mg) for two weeks
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (normal diet)
Number of subjects: 20
Study: 22774385

Group type: EXPERIMENTAL
Intervention: Community health workers (CHWs) intervention with a 16-hour training session and a 6-week tailored educational program.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Weekly lectures by clinical experts (Control group).
Number of subjects: 0
Study: 19930245

Group type: EXPERIMENTAL
Intervention: Single dose of propofol 2 mg/kg with supplemental doses of 0.5 mg/kg as needed, followed by normal saline infusion at 0.3 ml/kg/h.
Number of subjects: 160

Group type: COMPARATOR
Intervention: Continuous infusion of propofol after initial sedation.
Number of subjects: 160
Study: 18538243

Group type: EXPERIMENTAL
Intervention: Fixed functional orthodontic appliance (Forsus nitinol flat‐spring, 3M Unitek Corp, Monrovia, Calif) for 7 months
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Fixed functional orthodontic appliance
Number of subjects: 60
Study: 16334716

Group type: EXPERIMENTAL
Intervention: Acupuncture combined with point-injection therapy
Number of subjects: 30

Group type: COMPARATOR
Intervention: Basic neural medical treatment
Number of subjects: 30
Study: 12185427

Group type: EXPERIMENTAL
Intervention: Pressure- and volume-limited ventilation
Number of subjects: 120
Study: 10598967

Group type: EXPERIMENTAL
Intervention: AV node ablation and pacemaker implantation after discontinuation of rate-control medications
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: AV node ablation and pacemaker implantation without discontinuation of antiarrhythmic rate-control drugs
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pacemaker implantation without AV node ablation and continuing rate-control medical therapy
Number of subjects: 0
Study: 7564786

Group type: EXPERIMENTAL
Intervention: One-sided informed consent for randomisation
Number of subjects: 2035

Group type: EXPERIMENTAL
Intervention: Two-sided informed consent for randomisation
Number of subjects: 2035

Group type: EXPERIMENTAL
Intervention: Randomised consent to experimental treatment
Number of subjects: 2035

Group type: EXPERIMENTAL
Intervention: Randomised consent to standard treatment
Number of subjects: 2035
Study: 2009781

Group type: EXPERIMENTAL
Intervention: Low-dose amrinone (0.75 mg/kg loading dose + 10 micrograms/kg/min infusion)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: High-dose amrinone (2.25 mg/kg loading dose + 20 micrograms/kg/min infusion)
Number of subjects: 24
Study: 7120373

Group type: COMPARATOR
Intervention: 0% feedback schedule
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: 25% feedback schedule
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: 50% feedback schedule
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Feedback at left arm
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Feedback at both arms
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Feedback at right arm
Number of subjects: 36
Study: 30919382

Group type: EXPERIMENTAL
Intervention: Early P2Y12 inhibitor loading (clopidogrel)
Number of subjects: 60907

Group type: EXPERIMENTAL
Intervention: Early clopidogrel loading
Number of subjects: 60907

Group type: EXPERIMENTAL
Intervention: Early clopidogrel loading in ST-elevation myocardial infarction
Number of subjects: 60907

Group type: EXPERIMENTAL
Intervention: Early clopidogrel loading in non-ST elevation acute coronary syndrome (NSTE-ACS)
Number of subjects: 60907

Group type: EXPERIMENTAL
Intervention: Early loading with prasugrel and ticagrelor
Number of subjects: 60907

Group type: EXPERIMENTAL
Intervention: Early prasugrel loading in NSTE-ACS
Number of subjects: 60907

Group type: EXPERIMENTAL
Intervention: Timing of ticagrelor or prasugrel loading
Number of subjects: 60907
Study: 29975953

Group type: EXPERIMENTAL
Intervention: Thalidomide plus chemotherapy (CAG regimen with thalidomide at a maximum dose of 200 mg/day)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control arm (PC) - non‐intensive regimen composed of cytarabine, aclarubicin and G‐CSF (CAG) chemotherapy
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Thalidomide plus chemotherapy
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control arm (PC)
Number of subjects: 70
Study: 26173850

Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass (RYGB)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Biliopancreatic diversion with duodenal switch (DS)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Objective bulimic episodes before surgery
Number of subjects: 60
Study: 24739131

Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg/day for 8 weeks
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Atorvastatin 20 mg/day for 8 weeks
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg/day and 20 mg/day for 8 weeks
Number of subjects: 52

Group type: COMPARATOR
Intervention: Control group (healthy subjects)
Number of subjects: 52
Study: 22824595

Group type: EXPERIMENTAL
Intervention: Preoperative subconjunctival injection of mitomycin C (0.1 ml of 0.15 mg/ml) a day before surgery
Number of subjects: 50

Group type: COMPARATOR
Intervention: Topical application of mitomycin C during surgery (same concentration)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Preoperative subconjunctival injection of mitomycin C
Number of subjects: 50
Study: 19015231

Group type: EXPERIMENTAL
Intervention: Adjunctive antidepressant treatment for bipolar depression
Number of subjects: 176
Study: 17192668

Group type: EXPERIMENTAL
Intervention: Ispronicline (TC‐1734)
Number of subjects: 0